CHIUN HSUANN-LII CHENGPEI-JER CHEN2021-07-032021-07-0320090003-4819https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984568136&doi=10.7326%2f0003-4819-151-2-200907210-00014&partnerID=40&md5=6bf8e6cc7ce9ab0bc927c663cfc9751dhttps://scholars.lib.ntu.edu.tw/handle/123456789/568579[SDGs]SDG3corticosteroid; hepatitis B surface antigen; lamivudine; antiviral therapy; cancer chemotherapy; clinical trial; corticosteroid therapy; hepatitis B; human; infection prevention; letter; nonhodgkin lymphoma; priority journal; risk reduction; treatment duration; virus reactivationletter10.7326/0003-4819-151-2-200907210-00014196201692-s2.0-84984568136